Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial

This article was originally published here

The Calquence, obinutuzumab combination registered a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) during the trial, which was the primary endpoint. This was in comparison to the

The post Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply